Article3 Biotech2026
Matrine suppresses thymoma stemness and apoptosis via YTH N6-methyladenosine RNA binding protein 1 and Wnt/β-catenin signaling.
Article in 3 Biotech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymoma is a mediastinal tumor for which recurrence and therapeutic resistance remain clinical challenges, and cancer stem cell (CSC)-like properties may contribute to these features. This study investigated whether Matrine (Mat) affects stemness-associated features and apoptosis in EL-4-B5 cells and examined the potential involvement of YTHDF1 and Wnt/β-catenin signaling. Mat reduced cell viability and induced apoptosis, with the most evident effects observed at 100 µg/mL. Mat also reduced sphere-forming capacity and CD34 expression. Mat treatment decreased YTHDF1 expression and Wnt3a and β-catenin protein levels, whereas YTHDF1 overexpression or LiCl co-treatment partially attenuated these changes. Public-dataset analyses suggested potential clinical relevance of YTHDF1 in thymoma. Because direct m6A measurements, YTHDF1 target identification, in vivo validation, and clinical-sample validation were not performed, these findings support potential involvement of an m6A-related factor and Wnt/β-catenin signaling rather than establishing a definitive mechanism. Further validation is required before translational conclusions can be made. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-026-04956-z.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.